More
We are pleased to announce that Volume 137 of the IARC Monographs is now available online. This volume comprises three monographs: hydrochlorothiazide, voriconazole, and tacrolimus.
Hydrochlorothiazide is a thiazide diuretic primarily used to treat essential hypertension. Although it has increasingly been replaced by newer medications, hydrochlorothiazide remains a commonly prescribed drug because of the high prevalence of hypertension worldwide.
Voriconazole is a broad-spectrum triazole antifungal medication that is used to treat invasive aspergillosis and other serious fungal infections, which are especially common in transplant recipients.
Tacrolimus is an immunosuppressive medication that is mainly used to reduce the risk of organ rejection in adult and paediatric transplant recipients, and for the prevention of graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. Topical tacrolimus is indicated as second-line therapy for atopic dermatitis and vitiligo, as an alternative to first-line treatment with topical corticosteroids.
The IARC Monographs Working Group reviewed evidence from epidemiological studies, cancer bioassays in experimental animals, and mechanistic studies to assess the carcinogenic hazard to humans of exposure to these agents and concluded that hydrochlorothiazide, tacrolimus, and voriconazole are all carcinogenic to humans (Group 1).
